Vascular disease and stem cell therapies

Peripheral vascular disease is the leading cause of limb ischemia (LI). LI is manifested by claudication, ischemic rest pain, ulcers or gangrene. It is the result of peripheral arterial disease due to atherosclerosis. Over the last decade, several centers around the world have initiated clinical tri...

Full description

Saved in:
Bibliographic Details
Published in:British medical bulletin 2011-06, Vol.98 (1), p.187-197
Main Authors: LASALA, Gabriel P, MINGUELL, Jose J
Format: Article
Language:English
Subjects:
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Applied cell therapy and gene therapy
Biological and medical sciences
Clinical Trials as Topic - methods
Endothelial Cells - transplantation
Extremities - blood supply
General aspects
Humans
Ischemia - therapy
Medical sciences
Mesenchymal Stem Cell Transplantation - methods
Stem Cell Transplantation - methods
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Peripheral vascular disease is the leading cause of limb ischemia (LI). LI is manifested by claudication, ischemic rest pain, ulcers or gangrene. It is the result of peripheral arterial disease due to atherosclerosis. Over the last decade, several centers around the world have initiated clinical trials utilizing stem cells as a treatment for this disease. Published medical literature, clinical trials announced in clinical trials.gov and TCA cellular therapy experience. There is general agreement that stem cells are useful for LI. These arise from the type of cells, dose, route of administration and methods to evaluate efficacy. Growing evidence suggests that bone marrow derived-mesenchymal stem cells are as good as or superior to mononuclear cells, and a combination of both cell types may be even better. Based on current trials and publications, several promising biological products could become part of the therapeutic arsenal for LI. This may include combinations of more than one type of adult/induced pluripotent stem cells/embryonic stem cells, use of stem cells with growth factors or extracellular matrix molecules.
ISSN:0007-1420
1471-8391
DOI:10.1093/bmb/ldr017